ArticlePress releasePHN-05732026-11-02 05:00 CT

Superpower Launches Peptides, Connecting Prescription Peptide Care With Comprehensive Blood Testing

Source · PR Newswire

TLDR

Superpower announced a peptide-care program combining three compounds with blood testing and ongoing clinical support. The company says the compounded medications are not FDA-approved or authorized and that evidence of their safety and effectiveness in humans is limited.

01—Key points

01The announced lineup includes BPC-157, TB-500, and MOTS-C, with clinical evaluation, check-ins, and lab monitoring.
02The release says the program follows an interim HHS enforcement-discretion policy for compounding under specified safeguards while FDA rulemaking continues.
03The company cautions that the cited policy may be revised or rescinded and availability may vary by state.

Why it matters Editorial

The announcement links a commercial peptide-care expansion to a reported interim regulatory policy while acknowledging limited human evidence and lack of FDA approval.

Read the original at PR Newswire↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.